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ABBREVATION 
 
AF :Atrial fibrillation 
CAD :Coronary heart disease 
HF :Heart failure 
IVSd :Interventricular septal thickness in diastole 
LVIDd :Left ventricular internal diameter(cm) in diastole 
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INTRODUCTION 
Atrial Fibrillation is one of the frequently encountered arrhythmia (weak 
or irregular heart beat) in our population and it is the deranged supraventricular 
(atria) event mainly manifesting with irregular heart rhythm which in turn 
causes altered atrial - electrical and mechanical function. This also has a 
significant effect on economic burden to the society by causing both morbidity 
and mortality. Its prevalence though less than 1% in general population below 
65 years old ,its incidence and prevalence is in increasing trend of late1. 
Male sex is an important non modifiable risk factor when compared to 
female sex and additionally its incidence and prevalence are more in males than 
females. Incidentally females develop atrial fibrillation later in life after sixth 
decade when compared to male sex who develop bit earlier. White people are 
more affected than Black People. 
A large group of patients affected by atrial fibrillation are initially 
asymptomatic but in due course they end up with lot of complications, limiting 
the day today activities of affected population. Due to the abnormality in atrial 
activity there is abnormal atrial systolic event which leads to a deranged 
ventricular function with decreased output, leading up to formation of thrombus 
in atrium which finally ends up in cerebro vascular accident and thrombo-
embolic events. Pathophysiology of atrial fibrillation still remains in 
controversy, but there are many theories that have been proposed like “mother 
rotor theory” and “multiple wavelet theory”. 
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There are many comorbid conditions which contribute to the 
development of atrial fibrillation. Important diseases among them are 
Rheumatic valvular heart disease, Ischemic heart disease and Systemic 
hypertension. Smoking habit and alcohol consumption are risk factors adding to 
the development of such dysrhythmias. 
There are different types of atrial fibrillation where causes can be 
defined, but in undetermined or Lone AF no cause can be found. Different 
diseases causative to atrial fibrillation will appear at different ages, particularly 
atrial fibrillation appearing due to valvular heart disease appears earlier than 
other diseases which contributes to the development of atrial fibrillation. 
ECG shows irregular rhythm with normal or rapid rate, absent P waves, 
normal QRS Complex. Prime treatment method is pharmacological drug 
treatment while non-pharmacological treatment options are reserved for some 
patients. Of  late newer drugs and approaches under study. 
Many researches have been done to find out causes for atrial fibrillation 
and to frame guidelines for clinicians to decide treatment strategies. 
Echocardiography is beneficial in finding out the cause for development of 
atrial fibrillation and various echocardiographic parameters helps in predicting 
the risk for future development of atrial fibrillation and complications 
associated with atrial fibrillation. This study is intended to find out the varied 
presenting symptoms of AF and also possible underlying predisposing factors- 
cardiac and non-cardiac in Indian context. 
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AIMS AND OBJECTIVES 
• To study the various clinical presentations of atrial fibrillations admitted 
in Kanyakumari Govt. Medical College Hospital  
• To assess the frequency of underlying heart disease in patients with atrial 
fibrillation 
• Correlation with atrial chamber size with the help of echocardiography 
REVIEW OF LITERATURE 
Atrial fibrillation is basically a Supraventricular tachyarrythmia with 
uncoordinated activity of atria characteristically resulting in disordered atrial 
mechanical and electrical function1.Electrocardiographically characterized by 
low amplitude baseline oscillations called as Fibrillatory or ‘F’ waves and an 
irregularly irregular rhythm of ventricles with the rate of 300 to 600 beats per 
minute and they are variable in amplitude, shape, and timing. 
Picture 1: 
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Atrial fibrillation has been involved with the careers of many great 
clinicians and researchers of twentieth century2.The first description of atrial 
fibrillation was mentioned in “Harmony and Health in the Huang TiNei Ching 
Su Wen”(The Yellow Emperor’s Classic of Internal Medicine).He is the 
physician as well as emperor3.The term “Fibrillation” was first coined after 
demonstration of fibrillation of auricles by William Harvey in animals. Jean 
Baptist de Senac later described relationship between palpitation and stenosis of 
mitral valve. In 1827 in “Dublin Master of Clinical Expression” Robert Adams 
mentioned about the association of irregular pulse and mitral stenosis. The first 
person who put out human ECG portraying atrial fibrillation was William 
Einthoven in the year 1906.Sir Thomas Lewis who was known as “Father of 
modern ECG” described about elctrophysiological characteristics of AF whose 
basic mechanism is circus movement of electrical impulse that is “Re-entry”. In 
the 20th century various clinical features and pathophysiology was described by 
karel Fredrick wenkebach, Gordonmoe, Bernhordlown and maurits Allessie4. 
EPIDEMIOLOGY: 
Atrial fibrillation is the most common type of arrhythmia encountered 
and treated in current practice. Among arrhythmia related admissions in hospital 
33% are due to AF. Atrial fibrillation should be given its due importance due its 
worldwide distribution which is on the rise and it is the commonest arrhythmia. 
Indeed renowned scientist Braun wald once in his studies insisted on “growing 
Epidemic” of AF5.There is increase in CVA by 5 fold and cardiac failure6 by 
three fold, which in turn increases morbidity and mortality. In our country there 
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is no proper epidemiological data available on AF, but in recent times there is a 
data about Indian patients from RELY and REALIZE Studies (Indian patient 
cohort). IHRS-AF registry is the largest study in Indian population in relation to 
atrial fibrillation7. 
Incidence of Atrial fibrillation is related to age and sex and the 
distribution is such a way that while the prevalence is around 0.1% per year 
before the age of 40 years,  it is higher than 1.5% per year in female population 
and higher than 2% per year in males older than 80 years. In the western 
country prevalence of AF is 1.5-2% in general population, and the average age 
of presentation of disease is 75-85 years, When annual incidence was analysed 
it is 3.1 in males and 1.9 in females per 100 person years in persons whose age 
are below 65 years 8 .From one another population based research done recently 
in patients older than 65 years the prevalence in women is 4.85% lesser than 
that of men 9.1%9. In Framingham heart study the results were in such a way 
that AF developed 1.5 times more in males than in females. 
Similarly when obesity is associated with increasing age there is a 60% increase 
in AF Incidence. Due to absence of prominent symptoms incidence and 
prevalence of AF is often underestimated and its one of important limitations in 
understanding the epidemiology of AF. 
The first study regarding AF to be done in India was way back in 1995 
which included around 984 patients. The study showed a prevalence of 0.1%. 
The study had a lower prevalence because those who were recruited for study 
were healthy and was subjected to only single ECG, and around 6% of them 
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were above 65 years old. Another study famously known by name west 
Birmingham study showed a prevalence of 6% among Indians. Another 
community based study showed age adjusted incidence of AF per 1000 person 
years increased between 1980 and 2000 from 4.4 to 5.4 in men and from 2.4 to 
2.8 in women 10. 
AF is also mainly associated with double the time risk for all cause of 
mortality. Mortality increases in a person with AF even if he is normal 
otherwise. “Framingham study” shows Atrial fibrillation independently 
associated with increase in risk of mortality in men (OR: 1.5; with 95% CI: 1.2- 
1.8) and women (OR: 1.9; 95% CI: 1.5 – 2.2). 
Similarly AF is also linked with fivefold increase in risk for Stroke11, A 
study done revealed that globally AF may be the basic reason behind around 
75000 strokes per year and also it is one of the important causes of embolic 
stroke. When associated with other co morbidities like diabetes, hypertension 
and CAD there is further increase in chance of development of Stroke. 
PATHOPHYSIOLOGY: 
Anatomical modifications ending up alteration of atrial architecture 
possibly leads to progression of AF12.These structural changes include mainly 
inflammation, hypertrophy and fibrosis. These changes occur particularly due to 
basic cardiac disease like as follows 
 Coronary Heart Disease 
 Valvular Heart Disease 
 Hypertension 
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 Heart Failure And  
 Cardiomyopathies  
All above said conditions causes dilatation of atrium, changes or increase 
in wall stress, raised left atrial pressure. Similarly ischemia of atrium due to 
underlying coronary artery disease and other conditions like  
 Hemochromatosis 
 Amyloidosis 
 Sarcoidosis  
Also have high chances of developing AF.  The finding supporting this 
was done in a study where patients who had paroxysmal AF without any 
underlying structural heart disorder was evaluated with biopsy from atrium 
which revealed infiltrate of inflammation consistent with fibrosis and 
myocarditis13. 
Other factors which have pathologic effects on cellular function and 
atrium are extracardiac conditions like  
 Systemic hypertension 
 Obesity 
 Obstructive sleep apnoea syndrome 
 Hyperthyroidism 
 Alcohol and  
 Drugs. 
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Most common and repeated pathologic feature seen in AF is  
1. Atrial fibrosis  
2. Atrial muscle mass loss 
3. Inter nodal tract muscle loss.  
Mild to moderate fibrosis occurs in patients with AF of lesser duration 
whereas loss of muscle mass and severe fibrosis occurs in chronic AF. 
Myocardial fibrosis is the predominant feature of atrial fibrillation commonly 
seen in both human and experimental animal, atrium is very sensitive to pro-
fibrotic signalling pathways than that of ventricles because it contains large 
quantity of fibroblasts and hence these changes happens predominantly in 
atrium. 
Rapid ventricular pacing in experimental animals yields atrial fibrosis 
thereby making them susceptible to AF, similarly during rapid atrial pacing also 
fibrosis occurs. Rapid pacing of atrium for extended periods increases 
susceptibility to AF. These rapid pacing causes alteration in mitochondria, loss 
of myocyte from glycogen deposits and abnormal gap junction which lead to 
Apoptosis and cell necrosis14.For identification and quantification of the 
fibrosis15best used investigative method is non-invasive gadolinium 
enhancement MRI. This fibrosis has strong correlation with the development of 
stroke which is proven by many studies 16. 
Atrial dilatation also occurs due to systemic hypertension, coronary heart 
disease, dilated cardiomyopathy while all these factors leads to stretching of 
myocardium, which in turn activates various molecular mechanisms like Renin-
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Angiotensin-Aldosterone pathway, Angiotensin-II, TGF-α. These mechanisms 
in turn induce inflammation and production of connective tissue growth factors 
and fibrosis. Microscopic and macroscopic changes appear in the atrium as 
early as first year of life. During 4th to 5th decades droplets of fats appears in the 
region of Atrio ventricular node and septum, whereas in much older persons 
ageing results in myocardial fibres loss and fatty deposition. Histologically 
Patchy fibrosis with juxtaposed normal atrium contributes to such heterogeneity 
of atrial conduction. 
In rheumatic heart disease patient we can see the presence of Ascoff bodies 
pathognomonic of RHD, Anitschkow cells otherwise called as Caterpillar cells, 
Fish mouth appearance of valves are present particularly involving atria. 
MECHANISMS OF ATRIAL FIBRILLATION: 
There are lot of mechanisms which adds up to the development of AF, 
this mechanism may differ in each patient while sometimes all mechanisms may 
coexist in an individual patient. Mechanisms causing the development of AF 
and maintaining its course is more complex. The events which trigger this may 
differ from maintenance mechanisms. AF is more commonly initiated by small 
re-entrant or rapidly firing focus in the sleeves of atrial musculature along the 
pulmonary veins. 
The clinical Phenotypic variation of atrial fibrillation are 
 Paroxysmal 
 Persistent and  
 Chronic AF  
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have electro physiologically different features, because of remodelling 
and clinical modulators of different variety that affect the factors such as atrial 
stretch, myocardial ischemia, cardiac failure, inflammation, fibrosis, 
sympathetic and parasympathetic influences. There are basically two principle 
electrophysiological mechanisms which are the reasons behind development of 
such fibrillatory activity.  
They are Automatic, triggered or foci of micro re-entry called as Drivers. They 
fire at rapid rates and produce fibrillatory activity. Multiple Re-entry circuits 
that meanders the entire atrium annihilates and reforms wavelets which 
ultimately leads to accentuation of fibrillatory activity. 
 
In many instances these two mechanisms may be present together. 
Studies show that the site of dominant frequency of discharge is in left atrium, 
with a left to right gradient. One of a study done recently in which patients were 
subjected to multiple electrocardiograms recorded simultaneously associated 
with signal processing technique by obtaining computerized maps revealed foci 
of fibrillatory sources and electrical rotors. In that study a mean of 2.1 sources 
was found in 97 % of 101 patients, of which 30% was Focal sources and 70% 
was Motor Rotors17. 
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Figure1: Principal atrial fibrillation (AF)–maintaining mechanisms.  
 
MECHANISM OF TRIGGERS IN AF: 
Ectopic Focal discharges are often the provoking event in the 
development AF18. Anatomical and electrophysiological specific characteristics 
of atriopulmonary vein junctions and pulmonary veins are mainly guilty for 
arrythmogenic tendency. Particularly in patients with paroxysmal AF rapid foci 
of discharges often arises from sleeves of myocardium of LA that extend to 
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pulmonary veins. Hence this mechanism makes the basis for the radio frequency 
catheter ablation by doing pulmonary vein isolation. 
Re-entry mainly occurs because of conduction disturbances which leadto 
comparatively depolarized resting potentials in pulmonary vein myocytes, 
refractoriness in pulmonary veins and shortened action potentials. All these 
three changes favour the development of re-entry19. Sometimes pulmonary vein 
myocytes causes abnormal automaticity and trigger alone. 
Other sites for development of ectopic foci of discharges includes  
 Coronary sinus 
 Septum 
 Venae cavae 
 Posterior LA 
 Marshall Ligament. 
There are other sources of abnormal activity triggers present in pulmonary 
veins, which includes 
1.Interstitial cells20, 
2. Melanocytes21, 
Other conditions which cause a delayed after-depolarization include 
intracellular calcium metabolism derangement due to diastolic calcium leak 
from sarcoplasmic reticulum. This also plays an important role in the 
occurrence of AF22. 
COMPLEX FRACTIONATED ATRIAL ELECTROGRAMS: 
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In persistent type of AF atrial substrate changes including interstitial 
fibrosis which give rise to slow, anisotropic and discontinuous conductions lead 
on to “complex fractionated atrial electrograms” and re-entry. 
 
Figure 2: Models of re-entry. A. Leading circle, B. Spiral wave re-entry 
 
FACTORS RESPONSIBLE FOR MAINTENANCE OF AF: 
The following theories give explanation to the maintenance AF which includes 
1.Rapidly firing foci, which is responsible for activity from ganglion 
plexus present in the cardiac tissue. 
2.Re-entrant wavelets of independent in nature, in multiple quantities 
associated with conduction and refractoriness of heterogeneous nature. 
3.Spiral wave Re-entrant circuits or,  Rotors23. 
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Rotor excitation with a single rapid focus, leads to refractory tissue and breakup 
of wave fronts during propagation, resulting in fibrillatory or irregularly 
irregular conduction24. 
Above mentioned factors leads to the development of multiple treatment 
strategies. 
1. Rapid drivers in less quantity were identified in a group of patients with 
different types of AF using Biatrial phase mapping25. 
2. Ablation lines, maze procedure in atrium interrupts the pathways of 
Spiral re-entry and multiple wavelets. 
3. Continuous biatrial mapping using non-invasive methods gives different 
results. There is a role mostly for focal sites and multiple wavelets than 
Rotor Activity26. 
ROLE OF AUTONOMIC NERVOUS SYSTEM: 
AF is provoked by parasympathetic and or sympathetic 
stimuli27.parasympathetic and or sympathetic activation will lead to provoking 
of arrhythmias in atrium28. 
Sometimes activation of specific potassium current, IK, Ach, leads to 
shortened atrial duration of action potential and refractoriness heterogeneously, 
in turn increasing the predisposition to Re-entry. Sympathetic stimuli also 
sometimes cause a rise in intracellular calcium level causing atriggered activity 
and automaticity. Near the pulmonary vein-LA junctions and the ligament of 
Marshall there is some amount of epicardial fat is present in which autonomic 
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ganglionic plexus is also present, stimulation of this ganglia sometime produces 
rapid atrial activity. 
AF also occurs during conditions of high parasympathetic tone, such as 
following meals and during sleep, even in persons with structurally and 
physiologically normal heart called as “vagally mediated AF”. During exercise 
“stimulation of adrenergic system” also provokes AF in some of the patients29. 
Progression from paroxysmal to persistent AF occurs over a period of 
time, if AF duration is less than 6 months cardio version of AF and maintaining 
in sinus rhythm will be successful30. Studies demonstrate that AF produces 
structural and electrical remodelling such that “AF begets AF” consistent with 
progressive nature of atrial fibrillation31. 
 
Figure 3: AF Types–promoting remodelling. 
Electric remodelling is basically characterized by reduction in duration of 
action potential duration because of AF and there will be increased risk of 
delayed after depolarization. Whereas Structural remodelling is mainly due to 
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death of cells, proliferation of fibroblast and more extracellular matrix (ECM) 
production which ends up causing fibrosis. This fibrosis formed will prevent 
electric propagation and favours re-entry. Such interactions between Fibroblast-
cardiomyocyte activate re-entry and ectopic impulse production.  
 
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM: 
Electrophysiological and structural changes in the atrium and ventricle 
rises the vulnerability to arrhythmia which are caused by stimulation of renin-
angiotensin-aldosterone system32. The effects by this RAAS system which are 
responsible for causing AF are as follows  
1. Hemodynamic adverse effects, 
2.Increased intracellular calcium from activation of multiple cell 
signalling cascades, 
3. Apoptosis 
4. Hypertrophy 
5. Oxidative stress 
6.Cytokine release and inflammation, 
7.Growth related factors that promote fibrosis, 
8. Modulation of gap junction and ion channel dynamics. 
If there is any variation occurring in the ACE gene expression it ends up 
in increasing the plasma concentration of angiotensin-II thereby elevating the 
risk of AF. 
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Similarly increased in selective expression of ACEs results in dilatation of 
atrium, fibrosis and increase in vulnerability to AF. Increase in components of 
renin-angiotensin-aldosterone system synthesized in atrial myocardium during 
atrial tachypacing is one another mechanism attributed to development of 
AF.Aldosterone has a stellar part in angiotensin-II mediated inflammation and 
fibrosis in atria and hence due to this incidence of AF is more in patients with 
primary hyperaldosteronism. 
Previous studies done show that in experimental models of heart failure, 
Eplerenone and Spiranolactone decreases predisposition to both AF and atrial 
fibrosis, in these basis patients given eplerenone were associated with decreased 
occurrence of AF in heart failure patients33. 
INFLAMMATION AND OXIDATIVE STRESS: 
These mechanisms also play a role in development of AF which includes, 
Increase in plasma concentrations of CRP during inflammation linked with 
development of AF34. In case situations like associated with cardiac surgery and 
pericarditis such mechanisms happen. 
2.Interleukin-6 and C-reactive protein are generally raised in patients with AF, 
so this increased levels of C-reactive protein predicts the development of AF 
and also it predicts the relapse of AF after cardioversion. 
3. If there is variation in Gene expression promoter region of interleukin-6 it 
may sometime influence the development of AF in post-operative patients. 
4. Factors like ageing, inflammation, activation of renin-angiotensin-aldosterone 
system, Environmental stress also sometimes cause oxidative damage to atrium. 
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5. When there is upregulation of genes of reactive oxygen species because of 
oxidative damage it ends up in causing oxidative changes in atrium of patients 
with AF. 
6. There is increase in production of atrial superoxide due to apparent 
contribution of NAD(P)H oxidase particularly in patients with AF and also in 
experimental animal models35. That’s why when we give antioxidant Ascorbate 
post-operatively it decreases the electrical remodelling and thereby decreased 
AF36. 
Many researches about genetic forms of AF have been under work for 
many years but incidence of genetic type of AF is very rare37, while few 
population based studies suggest that AF is a heritable disease38.If there is 
family history of AF in a first degree relative it will independently increase AF 
risk by 2 fold38.Polygenic inheritance is more common than monogenic 
inheritance in the causation of AF because ion channels are principally affected 
by monogenic inheritance39.Genetic linkage studies done in the past have 
identified the potentially pathogenic loci responsible for development of 
AF40.Multiple liability signals are identified at chromosome 4q25 loci41. These 
foci are responsible for expression of transcription factor PITX2; any alteration 
of this factor is responsible for AF42. 
Familial AF is may be due to several mutations, their role in causation 
have been studied and identified43. These mutations are as follows 
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1. Gain of function mutation which causes repolarization of potassium 
currents which in turn leads to a decreased facilitation of atrial re-entry and 
atrial refractoriness. 
2. Many polymorphisms in the causation of AF are idiopathic and they 
are particularly related with heart diseases having structural anomaly or occurs 
postoperatively in patients 43. 
3.Because of these polymorphisms genes liable forconnexion, sarcolipin, 
RAAS, eNOS, sodium and potassium channels, interleukin-10, sarcolipin all are 
affected. 
4. The final impact due to this includes changes in conduction, fibrosis, 
and calcium handling which are the predisposing factors in the development of 
AF. 
CAUSES OF ATRIAL FIBRILLATION: 
There are so many causes or risk factors which produces the risk of AF which 
includes, 
CARDIAC 
1. Systemic Hypertension 
2. Ischemic heart disease 
3.Rheumatic mitral valve disease 
4.Hypertrophic and dilated cardiomyopathy 
5.Congestive cardiac failure 
6.Diastolic dysfunction and heart failure  
7.Pericarditis and Myocarditis 
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8.Post cardiac surgery 
9.Sick sinus syndrome 
10. Atrial septal defect 
11.Restrictive cardiomyopathy 
12.Mitral valve prolapse syndrome 
13.Increased pulse pressure  
NON –CARDIAC 
1. Smoking 
2. Exercise 
3. Genetic 
4. Familial 
5. Amyloidosis 
6. Drugs like theophylline 
7. Pneumonia 
8. Pulmonary embolism 
9. Diabetes 
10. Age 
11. Hyperthyroidism 
12. Alcohol intake 
13. COPD 
14. Obstructive sleep apnoea 
15. Pulmonary sleep apnoea 
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REVERSIBLE OR TEMPORARY CAUSES44, 45:- 
1. Post cardiac or thoracic surgery 
2. Myocardial infarction 
3. Pericarditis and Myocarditis 
4. Pneumonia 
5. Pulmonary embolism 
6. Holiday heart syndrome( Binge Alcohol intake) 
7. Hyperthyroidism 
8. Electrocution. 
AF also occurs in some cases of Wolff-Parkinson-white (WPW) 
syndrome, atrial ectopic tachycardia, AV nodal re-entrant tachycardia and also 
resolves after catheter ablation therapies for these arrhythmias46. 
ELECTROCARDIOGRAPHIC RISK FACTORS:- 
-Left ventricular hypertrophy 
ECHOCARDIOGRAPHIC RISK FACTORS:- 
-Left atrial enlargement 
-Increased LV wall thickness 
-Decreased LV fractional shortening 
BIOMARKERS:- 
-Increased brain natriuretic peptide (BNP) 
-Increased C-reactive protein (CRP)   
To discuss risk factors in detail foremost is hypertension, most of the 
patients with AF have systemic hypertension usually with left ventricular 
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hypertrophy,14% of all cases of AF have associated systemic hypertension48 as 
important risk factor .Apart from overt hypertension those patients with even 
prehypertensive range and wide pulse pressure also have significant risk of 
developing AF. 
Next important risk factor is Coronary heart disease, AF is a frequent 
problem encountered in acute coronary syndrome49.There is increased 
prevalence of both obstructive and non-obstructive CAD in patients with AF 
than patients without AF. 
Similarly valvular heart disease increase the risk of AF with 1.8 to 3.4 
times in male and female respectively48, even though any type of valve lesion 
can lead to AF left sided valvular heart disease particularly rheumatic heart 
disease has increased prevalence. Based on many previous studies it was 
identified that the following lesions has predisposition to AF50 
Isolated mitral stenosis – 29% 
Isolated mitral regurgitation -18 % 
Coexisting mitral stenosis and regurgitation – 52% 
Mixed mitral and tricuspid regurgitation -70%. 
In developing countries rheumatic heart disease is the most common cause of 
AF that too mitral stenosis is the most common cause of AF, and it is more 
common in women than men51. When compared with western countries Indian 
patients with RHD develop AF 15- 20 years earlier 52. 
One another important risk factor is hypertrophic cardiomyopathy which 
has been associated with 10% to 28% of AF cases53.Heart failure and AF often 
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coexist in such a way that when there is increasing symptoms of heart failure 
there will be increase in prevalence of AF 
The range of increase in prevalence in failure patients based on severity is 
as follows 
NYHA class I = <5% to 10% 
 NYHA class II-III =10% to 26%  
NYHA class IV = 40% to 50%54. 
Cardiac failure increases the risk of AF by 4.5 to 5.9 fold48.Apart from 
systolic heart failure sometimes isolated diastolic heart failure also increases the 
incidence of AF55. 
In congenital heart diseases there is increased prevalence of atrial 
tachyarrythmias56and also it is one of the most common complications in adult 
patients who presents with congenital heart disease. Among the congenital heart 
diseases particularly tetrology of fallot, atrial and atrioventricular septal defects, 
left sided obstructive heart diseases, Ebstein anomaly are associated with 
increased prevalence of AF , the main reason behind development of AF in all 
above  disease is atrial macro re-entrant arrhythmias . In these lesions left sided 
hemodynamic changes have animportant role as AF risk determinants57. 
Thyroid dysfunction is strongly associated with development of AF; 
increased risk of AF is related with overt hyperthyroidism with increased risk 
around 3 to 6 times than that of persons who are euthyroid. Hence there is linear 
relationship between AF risk and thyroid function which has been shown by 
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previous studies. Hence with changes in levels of thyroid stimulating hormone 
there is increase in relative risk of developing AF which is around  
- 1.1 with euthyroid. 
- 1.2 times with subclinical hyperthyroid alone 
- 1.4 with subclinical hyperthyroid and suppressed TSH  
Compared with normal thyroid status58, in hyperthyroidism it has been 
hypothesized that increased trigger activity and increased automaticity because 
of more β-adrenergic activity predisposes to AF. 
Similarly obesity and obstructive sleep apnoea syndrome both are related 
with one another and both escalates the risk AF individually59, rise in systemic 
inflammatory response and dilatation of atrium are the reason for development 
of AF in obesity. Some previous studies done showed that for every unit 
increase in BMI, incident of AF rises by 3% to 7%60. Some possible 
mechanisms postulated in development of AF in sleep apnoea syndrome are 
 Hypoxia and autonomic tone surge 
 Hypertension. 
Diabetes mellitus has been associated with increased risk of 1.4to 1.6 
fold, not only because both have similar risk factor profiles like  
 Diabetes associated with CAD 
 Heart failure 
 Obstructive sleep apnoea  
 Autonomic dysfunction and  
 Systemic inflammation 
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But also longer duration of disease and poorly controlled glycemic 
control independently increases the risk AF61. 
Chronic kidney disease is associated with AF frequently and it further 
increases when associated with common risk factors. Risk of AF increases with 
severity of renal failure (e.g., with an eGFR of 30-59 and <30ml/min per 1.73 
m2, the increase in relative risk is 1.3-1.6 and 1.6-3.2 times respectively). 
Similarly end stage renal disease is linked with increased incidence of AF, 
adjusted relative risk of 1.67-1.7762. 
Regular moderate physical activity usually gives beneficial effects on 
cardiovascular system and decrease the risk of AF with regular physical activity 
whereas excessive or vigorous sports activity is linked with increased 
prevalence of AF63. In persons who do such vigorous activity more than three 
episodes of AF paroxysms are likely to occur in relation with vagal stimulation 
such as sleep, at rest and postprandial states compared with healthy people64. 
Alcohol consumption and AF relationship has been well known for 
several years. Acute paroxysmal AF is sometimes associated with binge alcohol 
intake(Holiday Heart syndrome).Though moderate intake of alcohol does not 
increase the risk of AF, heavy intake more than or equal to 36g/dl has a higher 
risk of AF. Also it has been studied that consumption and subsequent 
withdrawal from alcohol will result in factors like  
Impairment of vagal tone, 
Hyper adrenergic tone 
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Changes in conduction properties of atrium all are considered to be 
predisposes to AF65. 
Similarly smoking has also been related with increased risk of 
development of  AF with more risk in those who are smoking that is with 
highest percentile of more than 675 cigarette-years)66. Sometimes AF 
recurrence after catheter ablation is linked with regular tobacco use67. 
 
 
CLINICAL FEATURES 
SYMPTOMS: 
Symptoms of AF vary between patients and it  ranges from nil 
symptoms to severe disabling status. 
The most common symptoms are, 
 Palpitation, 
 Fatigue, 
 Shortness of breath, 
 Chest pain, 
 Syncope, 
Other less common symptoms are 
 Effort intolerance, 
 Fluttering or thumping in the chest, 
 Giddiness 
 Confusion 
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 Weakness 
 Reduced ability to exercise 
 Abdominal pain 
Patients with paroxysmal AF symptomatic most commonly present with 
asymptomatic episodes.25% of the patients with AF are almost asymptomatic 
and they mostly belong to the cadre of patients with persistent AF and elder age 
group. One uncommon symptom encountered in AF is syncope. Particularly in 
sick sinus syndrome it can be initiated by long sinus pause on termination of AF 
whereas in an AF patients with rapid ventricular rate syncope occurs due to 
either severe fall in blood pressure or because of vasodepressor 
(neurocardiogenic)syncope that is due to tachycardia induced trigger. 
SIGNS: 
 Hallmark of AF is an irregularly irregular pulse, 
 Pulse deficit: Because of short R-R intervals adequate time for left 
ventricular filling will not be there which causes low stroke volume and 
absent peripheral pulse. Hence causing “pulse deficit” in which compared 
to apical rate peripheral pulse will be less. 
 Jugular venous pulsations will be irregular and ‘A wave” will be absent 
 “First heart sound” is variable. 
 Absence of “ fourth heart sound”. 
Sometime the findings are associated with valvular heart disease or 
myocardial infarction. 
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CLASSIFICATION OF AF: 
They are commonly classified based on the duration of episodes of AF 
using “simplified scheme revised from the 2006 AF Full revision 
guideline”27.The following are the techniques were used to classify atrial 
fibrillation  
 Pacemakers 
 Implanted loop recorders 
 Defibrillators 
By using them we can describe the, 
 Rate 
 Frequency 
 Duration of abnormal atrial rhythms 
CLASSIFICATION: 
 Paroxysmal, 
 Persistent, 
 Long standing persistent 
 Permanent, 
 Non valvular 
Table given below has useful clinical relevance, that is we can predict the 
outcomes of treatment, such as catheter ablation which is better for paroxysmal 
AF than persistent AF27,even after restoring to sinus rhythm by cardio version, 
the duration of the episode(s) of AF is not known, in some patients both 
paroxysmal and persistent AF can occur together. 
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“Lone or undetermined AF” is commonly seen in individual’s more than 
60 years without any structural heart diseases or hypertension. 
COMPLICATIONS:- 
Some patients because of minimal symptoms or asymptomatic mostly 
doesn’t go for medical advice and their initial presentation itself sometimes 
present with stroke or thromboembolic complications. 
The most common complications are as follows 
Heart failure: 
Physiologically at rest almost 20% of left ventricular stoke volume is by 
atrial contraction which is pathologically reduced in AF and additionally it will 
cause LV dysfunction and irregular rhythm of ventricles68.AF also 
decompensate ventricular function. Hence a rise in prevalence of AF is seen in 
congestive cardiac failure. 
Thromboembolism: 
One of the most important complications of AF is thromboembolism and 
it is involved in the causing stroke in elderly patients with AF. The mechanism 
of thromboembolism is depicted by below image 
 
 
 
40 
 
 
 
 
 
 
 
 
 
Figure 4: During AF Dynamic interactions between atrial and 
ventricularfunction. 
 
 
 
 
 
 
 
 
 
 
Figure.5:Mechanism of AF related thromboembolism.  
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For many decades thrombosis-related clinical events have been 
essentially related to formation of thrombus in the left atrium with subsequent 
embolization in the cerebral and peripheral circulation. AF satisfies the criteria 
of Virchow’s triad, which are necessary for thrombus formation like blood 
stasis, endothelial dysfunction and clotting activation. Blood stasis is almost 
evident in the left atrium of AF patients where flow velocity is significantly 
reduced alongside impaired contractility of left atrial appendage. It is still 
unclear, however, if remodelling-related blood stasis is in fact involved in 
favouring thrombus formation in AF. This hypothesis has been recently 
challenged by some researchers who demonstrated that atrial remodelling as 
such does not influence clotting activation and thrombus formation. Endothelial 
dysfunction is another related component of Virchov’s triad which has been 
seen in patients with AF by measuring several markers of endothelial 
perturbation such as von Willebrand factor (vWf) and E-selectin. vWf is a 
glycoprotein secreted by endothelial cells in response to injury and it is usually 
measured to assess endothelial damage. Several studies consistently showed 
increased vWf levels in patients with AF. E-selectin is specifically present in 
endothelial cells and is raised in the blood circulation as a result of endothelial 
activation. Higher blood levels of E-selectin have been noticed in patients with 
several types of AF.  
Clotting activation is the third component of Virchow’s triad which may 
contribute to thrombosis-related clinical events in AF. Several studies have 
demonstrated that AF may induce a hyper-coagulation state as shown by 
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increase of plasma levels of F1+2, D-dimer and fibrinogen. Different authors 
have investigated the relationship between clotting biomarkers and ischemic 
events, but results are equivocal; for instance, there are not convincing 
evidences that fibrinogen is associated with left thrombus or may predict 
vascular outcomes in AF. A study done earlier showed a significant association 
between fibrinogen and ischemic stroke suggesting that coagulation system 
could be implicated in thrombosis-related ischemic events of AF. [18] 
3. Stroke: 
The most common complication in AF is thromboembolism induced 
stroke, AF is associated with 5 time higher chance of getting stroke. In a 
prospective study among patients with stoke, subclinical atrial tachyarrythmias 
(atrial rate>190 beats /min for 6 minutes) were detected by device interrogation. 
Hence subclinical atrial tachyarrythmia was independently associated with 
increased risk of stroke. 
Several echocardiographic parameters have been associated with 
increased risk for stroke in AF, including left ventricular hypertrophy, left 
ventricular systolic dysfunction, and left atrial enlargement. In a study 
performed by the SPAF investigators, left ventricular dysfunction on 2-
dimensional echocardiography was a strong independent risk factor for 
thromboembolism.29 Another prospective study in patients with AF also showed 
that moderateto-severe left ventricular dysfunction on echocardiography was a 
strong independent predictor of stroke.30Conversely, a subsequent study by the  
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Figure 6. Annual risk for stroke (percent risk per year) based on the CHADS2 
and CHA2DS2-VASc scores. (Based on data from Lip GY: Implications of the 
CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial 
fibrillation. Am J Med 124:111, 2011. 
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SPAF investigators failed to identify any echocardiographic parameters 
that were independently associated with thromboembolism. 
Left atrial size measured from the M-mode echocardiogram was shown to 
be a strong independent predictor of stroke in one study29 but not in a later 
study.30 Left atrial appendage length and width obtained via trans-oesophageal 
echocardiogram was shown to be associated with risk of thromboembolism on 
univariate analysis but not multivariate analysis.31 In the same study, thrombus 
in the left atrium or left atrial appendage was associated with increased risk of 
thromboembolism on univariate but not multivariate analysis.31 Another trans-
esophageal echocardiogram study showed that spontaneous echo contrast and 
complex atherosclerotic plaque in the thoracic aorta were independently 
predicative of thromboembolism.18 In summary, the incremental value of 
echocardiographic parameters for assessing stroke risk in patients with AF is 
still unproven. 
DIAGNOSTIC EVALUATION 
Initial diagnostic evaluation of AF includes, 
A)Minimum evaluation, 
B)Additional investigations, which all depends upon the presentation of 
patient’s clinical situation. 
Minimum: 
 Patient’s clinical history and physical examination findings 
 ECG 
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 Chest X-ray 
 Transthoracic Echocardiography 
 Blood investigations 
 
Additional investigations: 
 6- minutes walk test 
 Exercise testing 
 Holter or event monitoring 
 Transesophageal echocardiography(TEE) 
 Electrophysiological study. 
 
Clinical history and physical examination:  
Here we have to assess the following things, 
 Nature of the symptomatology  
 Clinical types of AF( paroxysmal, persistent, permanent) 
 Onset of first episode or day of detection 
 Frequency, duration, aggravating factors, modes of initiation and 
termination of AF 
 Response to any drugs administered 
 Presence of underlying heart diseases or any reversible conditions 
2. Electrocardiogram(ECG): 
ECG is the important and essential tool for confirming the diagnosis of 
AF; the following features are the ECG finding of AF, 
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 Very irregular and disorganized atrial activity represented as fibrillatory 
waves called as ‘F’ waves. 
 ‘F’ waves may be fine or coarse with varied morphology mistaken for P 
waves 
 Instead of ‘F’ waves, a flat line with irregular R-R intervals may be 
present. 
 Absent or no distinct P waves. 
 Atrial rate in AF is ≥350 beats/ minute 
 Ventricular rate is irregularly irregular and it is depends upon number of 
atrial impulses reaching atrioventricular(AV) node 
 Narrow QRS complex unless there is aberrant conduction, preexcitation 
or bundle branch block.  
 
Fig:ECG with Atrial fibrillation 
ECG is used to identify other features in an AF patient to find out other 
contributing factor or causative disease, 
 Rhythm to verify AF 
 Morphology and duration of ‘P’waves or ‘F’ waves. 
 Bundle branch block, pre-excitation 
 Previous MI, 
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 Other atrial arrhythmias 
ECG are helpful in patients who are taking anti arrhythmic therapy, to measure 
and follow, R-R intervals, QRS complex, QT intervals. 
 
Chest X-ray: 
Chest radiograph is done to find out any suspected pulmonary pathology 
contributing to AF also to identify suspected cardiac failure, to see any cardiac 
chamber enlargement. 
Transthoracic Echocardiography(TTE): 
Transthoracic echocardiography (TTE), including two dimensional (2D) 
imaging and complete Doppler assessment of valves, is recommended for all 
subjects with AF.2 TTE allows rapid, safe, relatively comprehensive assessment 
of cardiac structure and function that can help to define the underlying aetiology 
of AF and the risk of complications. Recent advances such as harmonic 
imaging, alone or with micro-bubble contrast agents, allow enhanced 
endocardial border definition for assessment of left ventricular volumes and 
function. New modalities such as colour M mode (CMM) and tissue Doppler 
imaging (TDI) allow more accurate assessment of diastolic function and 
estimated filling pressures. Assessment of systolic and diastolic left ventricular 
function in AF may, however, be complicated by irregular RR interval and rapid 
ventricular rate. Transthoracic imaging usually provides suboptimal 
visualisation of the atrial appendages and has inadequate sensitivity and 
specificity for diagnosing LAA thrombus. 
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Echocardiography hasan important role in management and risk 
stratification of patients with AF. Echocardiography has also become a 
fundamental part in the guidelines for management of patients with AF, 
especially in explaining the mechanisms of systemic thromboembolism in AF. 
Transthoracic echocardiography(TTE) allows broad and quick evaluation of 
cardiac anatomical structure and function. TTE is necessary for the initial 
evaluation of patient with first episodes of AF and gives evidences to find out 
the etiology of AF, and helps the physicians to start and decide the treatment 
approach. There are lot of studies shows that echocardiography helps the 
physicians in anemergency situation to take decision about antithrombotic 
prophylaxis. The following can be assessed by TTE. 
 Valvular heart disease 
 LA and RA size 
 LV and RV size and function 
 Left ventricular hypertrophy 
 LA thrombus(low sensitivity) 
 Pericardial disease.  
Left ventricular systolic dysfunction identified in TTE in patients with atrial 
fibrillation can independently predict the risk of stroke(relative risk 2.5; 
p<.001)69. 
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LA size is one another important predictor of recurrent AF, large left atrial 
size is linked with higher risk of developing AF70, if LA size exceeds >4.5Cm2 
cardioversion is unlikely to be effective71, LA size >4.0 Cm2 is a single most 
strong predictor of increased risk of embolization72even in the absence of other 
causes for increased atrial size, there is increase in size of atria with time in 
patients of AF73. 
 Chronic duration of AF 
 Increased muscle mass 
 Left ventricular dilatation. 
 Annular calcification 
 Mitral regurgitation 
 Hypertension  
These are the factors which independently influence the LA size. Data from 
the Framingham study shows that 39% increased risk for subsequent 
development of AF, if LA dimension increase by 5-mm74. 
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Echocardiography is also useful in evaluating the atrial function. Both LA 
compliance and volume reduction has been noted with the onset of AF and it 
also reduces cardiac function and in turn there will be increase in risk of 
thromboembolism. 
Similarly in patients with sinus rhythm, presence of severe LV diastolic 
failure is linked with a higher risk for AF and heart failure, as evaluated by 
ECHO. Septal thickness(IVSD) and left ventricular posterior wall thickness 
(LVPWD) are other independent factors influencing the prognosis of AF.  
They are also useful in predicting thromboembolism based on below features  
 Valve disease 
 Left ventricular systolic dysfunction 
 Left atrial dilatation 
 Complex aortic atheroma 
 Left atrial appendage thrombus > sludge > smoke 
 Reduced LAA velocities (< 20 cm/s) 
Blood investigations: 
In a patient with first episode of AF and in those whom ventricular rate is 
difficult to control following test are required 
Thyroid function test 
Liver Function test 
Renal function test. 
Additional investigations: 
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One are more of the following investigations may be required depending upon 
the clinical situations. 
 
 
 
TREATMENT 
The basic algorithm of management in atrial fibrillation is depicted below 
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Acute management: 
New onset AF: It presents with severe hypotension, pulmonary edema, or 
angina should be electrically cardioverted starting with aQRS synchronous 
shock of 200 J, ideally after sedation or anaesthesiais achieved. Greater shock 
energy and different electrode placements may be tried if the shock fails to 
terminate AF. If AF terminates and reinitiates, administration of an 
antiarrhythmic drug, such as ibutilide,and repeat cardio version may be 
considered. If the patient is stable,immediate management involves rate control 
to alleviate or prevent symptoms, anticoagulation if appropriate, and cardio 
version to restore sinus rhythm if AF is persistent.  
Anticoagulation strategies for newonset AF are debated. In the absence of 
contraindications, it is usually appropriate to initiate systemic anticoagulation 
with heparin immediately, while evaluation and other therapies are 
implemented. 
Acute rate control can be achieved with beta blockers, calcium channel 
blockers such as oral or i.v verapamil and diltiazem, Digoxin is added in patient 
with cardiac failure patients, because it does not have negative inotropic effects, 
particularly if use of AV nodal–blocking agents is limited by poor tolerance or 
is contraindicated. Its effect is modest but synergistic with the other AV nodal–
blocking agents, but it is particularly limited when sympathetic tone is elevated. 
Typically, the goal of acute rate control is to reduce the ventricular rate to less 
than 100/min, but the goal must be guided by the clinical situation. 
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Long term management of atrial fibrillation: 
1. Pharmacological rate control: 
According to ACC/AHA guidelines the following table describe about the 
pharmacological rate control measures. 
 
 
 
2. Rhythm control: 
a) Cardioversion 
First line drugs recommended for pharmacological cardio version includes the 
following drugs, 
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 Flecainide, 
 Dofetilide , 
 Propafenone , 
 Ibutilide. 
b) Direct – current (DC) cardio version; 
Recommended when the ventricular rate is rapid and does not respond quickly 
to drug therapy in patients with 
 Ischemic heart disease, 
 Hypotension, 
 Cardiac failure, 
 WPW syndrome, 
 Rapid ventricular rate, 
 Patients with hemodynamic instability. 
c)Maintenance of sinus rhythm: 
According to ACC/AHA guidelines the following table describe about the 
maintenance of sinus rhythm measures. 
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B)Special situations: 
Post-operative Atrial fibrillation:  
Prophylactic treatment with beta blocker to prevent post-operative AF in 
patients planned for cardiac surgery. 
Acute Myocardial Infarction:  
Electrical cardio version is recommended for patients with hemodynamic 
compromises or ongoing ischemia or when drugs failed to control the rate. 
AF in WPW syndrome:  
Catheter ablation of the accessory pathway is recommended for patients 
with symptomatic AF in WPW syndrome. 
Hyperthyroidism:   
Beta blockers are the first line drugs for rate control in thyrotoxicosis 
patients with AF. 
Hypertrophic Cardio myopathy: 
 The drugs used preferably either disopyramide with beta 
blocker,verapamil, or diltiazam or amiodarone for rate control. 
 
AF during Pregnancy:  
Recommended drugs are dioxin, beta blocker or a nondihydropyridine 
calcium channel antagonist for rate control. DC cardio version is recommended 
in hemodynamically unstable patients. 
Pulmonary Disease:  
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Verapamil or diltiazam is used for rate control in patient with COPD. 
Prevention of Thromboembolic Complications: 
The main aim of treatment in patients with AF is to prevent 
thromboembolic complications such as stroke. There are two scoring systems 
have developed for ‘risk stratification’ they are as follows, 
1. CHADS2scoring system: 
A simple method to “risk stratify” patients is based on “CHADS2 score” By 
using this scoring system we can predict the direct relationship between 
CHADS2 score and the annual risk of stroke in patients with AF in the absence 
of warfarin or aspirin treatment, this score is very simple and it has predictive 
value. 
2. CHA2DS2-VASc scoring system: 
But recent studies have shown that” CHA2DS2–VASc score” more accurately 
differentiates low risk from intermediate risk patients. 
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Based on the scores the therapies are recommended as follows, 
Aspirin is used prophylatically when” CHA2DS2–VASc score” of 0. 
Aspirin for stroke prevention is recommended for patient with ‘CHADS2score 
‘of0. 
3. Aspirin and or oral anticoagulant,When the CHADS2 score is 1. 
 
Newer Anticoagulants:  
Dabigatran, Rivaroxaban and apixaban for patients with AF in whom 
maintenance of therapeutic INR during treatment with warfarin is difficult. 
Low molecular heparin is an alternative to unfractionated heparin for initiation 
of anticoagulation with warfarin. 
Surgical removal or closure of LA appendage. 
“HAS –BLED scoring system” was developed to risk stratify patients 
susceptible for bleeding complications. As the score increases from 0 to 
maximum of 9, there is a gradual increase in bleeding in patients treated with 
warfarin. 
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D) Non pharmacologic management of AF: 
The following are the non-pharmacological options available for management 
of AF, 
 Pacing, 
 Catheter ablation, 
 Surgical removal or closure of  LA appendage, 
 Maze procedure. 
Atrioventricular  junction ablation with pacing is an effective strategy for a 
small number of highly symptomatic patients with AF, but it is highly invasive 
and creates dependence on an implanted pacemaker. It is commonly considered 
in patients with AF in whom neither sinus rhythm nor rate control can be 
achieved nor in patients who already have a pacemaker for bradycardia-
tachycardia syndrome. Several studies have shown improved quality of life and 
improvement in ventricular function with this strategy. In patients with 
symptomatic heart failure and permanent AF, biventricular pacing can also be 
useful with atrioventricular junction ablation. 
Various pacing strategies, including multi-site atrial pacing, atrial anti-
tachycardia pacing, and atrial defibrillator therapy, have been tested for the 
prevention and treatment of AF, but no studies have convincingly shown a 
significant benefit for these patients. 
In patients with primary typical right atrial flutter which degenerates into AF, a 
"hybrid" procedure involving atrial flutter ablation and treatment with an 
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antiarrhythmic drug may be an effective strategy. However, this population 
represents only a small minority of AF patients. 
The surgical Maze procedure was developed nearly 2 decades ago, and clinical 
results have been quite good, with reported success rates of over 90% in many 
trials. However, the requirement for open-heart surgery has necessarily 
restricted this therapy to patients undergoing cardiac surgery for other 
indications. 
JUSTIFICATION OF STUDY 
• Atrial fibrillation(AF) is the most common sustained cardiac arrhythmia 
in clinical practice and increasing in prevalence 
• Atrial tachyarrhythmia characterized by predominantly uncoordinated 
atrial activation with consequent deterioration of atrial mechanical 
function 
• Prevalence roughly doubles with each advancing decade 
• This study is intended to find out the varied presenting symptoms of AF 
and also possible underlying predisposing factors- cardiac and non-
cardiac in Indian context 
• If identified early and treated properly, AF rarely causes serious or life-
threatening complications 
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MATERIALS AND METHODS 
Study design: Cross-sectional study 
Study period: One year 
Study area: Govt. Kanyakumari Medical College and Hospital. 
Study population: Patients with New onset Atrial Fibrillation (in patients and 
out patients) in Department of General medicine and Department of Cardiology, 
Govt. Kanyakumari Medical College and Hospital. 
Sample Size: Was calculated based on α  level 5%[95% confidence interval], 
absolute accuracy at 9%, so by calculating by this sample size is 50.since inflow 
of patients with AF to our hospital is very high, I have taken up sample size as 
100 to my study. 
Ethical clearance: Ethics committee clearance was obtained. 
Consent: Informed consent obtained from all subjects for clinical examination 
and for doing investigations. Patient confidentiality maintained.  
Inclusion criteria: Patients aged more than 18yrs, Patients with clinically and 
electrocardiographically proven atrial fibrillation and hemodynamically stable 
patients. 
Exclusion criteria: Patients with atrial arrhythmias other than atrial fibrillation 
and hemodynamically unstable patients. 
Methodology: 
100 patients with Atrial fibrillation were analysed in this study, and their 
general and clinical data was included in the proforma. 
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Patient’s age, sex, clinical symptoms and past history of Systemic 
Hypertension, Rheumatic heart disease, Coronary Artery Disease, chronic 
obstructive pulmonary disease, Hyperthyroidism, Cardiomyopathy, Congenital 
heart disease, Stroke, and treatment history, were taken in to account. 
Diagnosis of atrial fibrillation was done by absent P waves, 
fibrillatorywaves, irregularly irregular ventricular rate in ECG were taken as the 
evidence for AF. Evaluation regarding etiology of AF is done by using ECG 
and Transthoracic echocardiogram, Chest radiograph were done in all patients. 
Diagnosis of Systemic hypertension was made by blood pressure with 
systolic BP > 140 mmHG and /or Diastolic BP > 90mmHG. 
Presence of ‘T’ wave inversion and Significant Q waves in ECG, 
Regional wall motion abnormality in ECHO were taken as evidences for 
coronary artery disease.COPD was diagnosed by using history of chronic cough 
and history of smoking, Chest radiograph, ECG, Transthoracic ECHO. 
Thyroid Function tests were done only for ‘at risk’ cases and those who are 
presenting with signs and symptoms of hyperthyroidism. History of smoking 
and Alcohol were asked in all patients. 
Clinical examination: 
 General examination 
 Vitals:- 
 Pulse rate, 
 Pulse deficit, 
 Blood pressure, 
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 Systemic examination, 
 Signs of hyperthyroidism, 
Laboratory data:- 
 Conventional 12 lead ECG with rhythm strip, 
 Transthoracic echocardiographic examination, 
 Complete blood count,  
 .Renal function test 
 Lipid profile Blood glucose levels-fasting and post prandial, 
 Chest Radiograph, 
 Thyroid function tests in selected patients, 
In our study, All patients were analyzed with 2D ECHO, M MODE and Colour 
Doppler to find out the coronary heart diseases, if structural heart disease like 
congenital heart diseases, hypertensive heart disease, and dilated 
cardiomyopathies, hypertrophic cardiomyopathy. 
Transthoracic echocardiographic assessment also includes the search for the 
presence of left atrial clot. 
Transthoracic echocardiography (TTE) was done in all patients and the 
following parameters were assessed. 
LVIDd(cm) 
Ejection fraction% 
5.RWMA 
6.Valvular  lesions 
7.RA and LA Size(cm) 
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8.LA Clot 
9.RV systolic dysfunction  
 
Analysis of Data: 
The different presentations of AF will be provided as % with 95% confidence 
interval. 
The different predisposing factors will be provided as %. 
The different parameters of  Transthoracic Echocardiography will be provided 
in %. 
The collected data were analysed with IBM.SPSS statistics software 21.0 
Version. To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean and S.D 
were used for continuous variables. To find the significant difference between 
the bivariate samples in Independent groups the unpaired sample t-test was 
used.To find the significance in categorical data Chi-Square test was used. In all 
the above statistical tools the probability value <.05 is considered as significant 
level. 
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RESULTS 
Table 1: Age distribution 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
<20 2 2% 
20-40 37 37% 
41-60 46 46% 
>60 15 15% 
 
Chart 1: Age Distribution
 
 
Among our study group most commonly patients were in 41-60 age 
group followed by 20-40 age group. 
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Table 2: Sex distribution 
SEX DISTRIBUTION NO OF PATIENTS PERCENTAGE 
MALE 37 37% 
FEMALE 63 63% 
 
Chart 2: Sex distribution 
 
Females were commonly seen in our study group more than males with a 
male female ratio of 1:1.7. 
 
Table 3: Past history of rheumatic heart disease 
PAST H/O RHD NO OF PATIENTS PERCENTAGE 
PRESENT 63 63% 
ABSENT 37 37% 
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Chart 3: Past history of rheumatic heart disease 
 
 
Among our study group around 63 patients had past history of rheumatic 
heart disease which one of most common etiology 
 
Table 4: Past history of coronary artery disease 
 
PAST H/O CAD NO OF PATIENTS PERCENTAGE 
PRESENT 17 17% 
ABSENT 83 83% 
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Chart 4: Past history of coronary artery disease
 
 
Among our study group around 17 patients had past history of coronary artery 
disease 
 
 
Table 5: Past history of systemic hypertension 
 
PAST H/O SHT NO OF PATIENTS PERCENTAGE 
PRESENT 29 29% 
ABSENT 71 71% 
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`  Chart 5: Past history of rheumatic heart disease
 
 
 
Among our study group around 29patients had past history of systemic 
hypertension 
 
Table 6: Past history of diabetes mellitus 
 
PAST H/O DM NO OF PATIENTS PERCENTAGE 
PRESENT 22 22% 
ABSENT 78 78% 
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Chart 6: Past history of diabetes mellitus
 
Among our study group around 22 patients had past history of diabetes mellitus. 
Table 7: Past history of COPD 
PAST H/O COPD NO OF PATIENTS PERCENTAGE 
PRESENT 13 13% 
ABSENT 87 87% 
 
Chart 7: Past history of COPD 
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Among our study group around 13 patients had past history of chronic 
obstructive pulmonary disease. 
Table 8: Other associated diseases 
OTHERS NO OF PATIENTS PERCENTAGE 
PRESENT 9 9% 
ABSENT 91 91% 
Chart 8: Other associated diseases 
 
Among our study group around 9 patients had history of other diseases. 
Chart 9: Other associated diseases 
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Table 9: Other associated diseases 
OTHER DISEASES NO OF PATIENTS PERCENTAGE 
HYPERTHYROIDISM 2 17% 
THYROTOXICOSIS 3 25% 
DCM 1 8% 
ATRIAL SEPTAL DEFECT 2 17% 
RCM 1 8% 
HOCM 3 25 
 
Among our study group patients had other diseases like thyroid disorders, 
cardiomyopathies and ASD. 
 
Table 10: Presenting complaints 
 
PRESENTING COMPLAINTS NO OF PATIENTS PERCENTAGE 
PALPIATATION 53 53% 
CHEST PAIN 26 26% 
BREATHLESSNESS 78 78% 
PEDAL EDEMA 35 35% 
GIDDINESS 6 6% 
WEAKNESS OF LIMB 7 7% 
OTHERS 4 4% 
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Chart 10: Presenting complaints 
 
 
Among our study group most common presenting complaints is 
breathlessness followed by palpitation. Chest pain is seen in 26 patients and 
pedal edema in 35 patients. 
Chart 11: Number of complaints
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Table 11:  Number of complaints 
NO OF COMPLAINTS NO OF PATIENTS PERCENTAGE 
ONE 32 53% 
TWO 32 26% 
MORE THAN TWO 36 78% 
 
In our study patients 32 patient’s presented with single complaints and 32 
patients with two complaints where as rest of patients presented with more than 
2 complaints. 
In our study group 25 patients had some sort of personal habits like 
smoking and alcohol intake.16 patients had smoking habit and 19 patients had 
habit of alcohol intake. 
Chart 13: Smoking habit 
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Table 13: Smoking habit 
 
SMOKING HABIT NO OF PATIENTS PERCENTAGE 
PRESENT 16 16% 
ABSENT 84 84% 
 
Table 14: Alcoholic habit  
ALCOHOLIC NO OF PATIENTS PERCENTAGE 
YES 19 19% 
NO 81 81% 
 
Chart 14: Alcoholic habit 
 
 
 
 
19%
81%
ALCOHOLIC
YES
NO
 
 
 
75 
 
Table 15: Cardiac failure 
CARDIAC FAILURE NO OF PATIENTS PERCENTAGE 
PRESENT 37 37% 
ABSENT 63 63% 
 
Chart 15: Cardiac failure 
 
In our study patients around 37 patients had symptoms of cardiac failure 
with different ranges of ejection fraction. 
Chart 16: Heart rate 
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Table 16: Heart rate 
 
HEART RATE NO OF PATIENTS PERCENTAGE 
SLOW 5 5% 
CONTROLLED 46 46% 
UNCONTROLLED 49 49% 
 
Around half of patients in our study (n=49) uncontrolled heart rate or 
tachycardia while rest had normal rate and only two patients had bradycardia. 
 
Table 17: Blood pressure  
 
BLOOD PRESSURE NO OF PATIENTS PERCENTAGE 
HIGH 32 32% 
NORMAL 46 46% 
LOW 22 22% 
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Chart 17: Blood pressure 
 
 
Abnormal blood pressure either high (n=32) or low (n=22) is seen in 54 
patients while the rest had normal blood pressure. 
 
Chart 18: Left Ventricular Internal Dimension-Diastole. 
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Table 18: Left Ventricular Internal Dimension-Diastole. 
 
LVIDd NO OF PATIENTS PERCENTAGE 
NORMAL 70 70% 
ABNORMAL 30 30% 
 
In our study group Left ventricular internal dimension during diastole 
was abnormal or increased in 30 patients among which the increase was mild in 
22 patients and moderate in 8 patients. 
 
Table 19: Abnormal Left Ventricular Internal Dimension-Diastole. 
 
ABNORMAL LVIDd NO OF PATIENTS PERCENTAGE 
MILD 22 73% 
MODERATE 8 27% 
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Chart 19: Abnormal Left Ventricular Internal Dimension-Diastole 
 
Table 20: Ejection fraction 
 
EJECTION FRACTION NO OF PATIENTS PERCENTAGE 
NORMAL 71 70% 
LOW 29 30% 
 
Chart 20: Ejection fraction 
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Table 21: Ejection Fraction 
 
EJECTION FRACTION NO OF PATIENTS PERCENTAGE 
> 55% 71 71% 
45-54% 16 16% 
30-44% 10 10% 
< 30% 3 3% 
 
Chart 21: Ejection Fraction 
 
 
 
In our study group decreased ejection fraction was seen in 29 patients 
amog which 16 aptients had mild decrease, 10 patients had  moderate decrease 
and 3 had severe reduction 
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Table 22: Regional wall motional abnormality 
 
RWMA NO OF PATIENTS PERCENTAGE 
PRESENT 15 15% 
ABSENT 85 85% 
 
Chart 22: Regional wall motional abnormality 
 
 
 
Regional wall motion abnormality was seen in 15 patients in our study group. 
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Table 23: Left atrial size 
 
LEFT ATRIAL SIZE NO OF PATIENTS PERCENTAGE 
NORMAL 39 39% 
ABNORMAL 61 61% 
 
Chart 23: Left atrial size 
 
 
 
Left atrial size is increased in 61 patients among which it was mildly 
increased in 41 patients, moderately increased in 14 patients and severely 
increases in size in one patient. 
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Table 24: Left atrial size 
 
LA SIZE NO OF PATIENTS PERCENTAGE 
NORMAL 39 39% 
MILDLY ABNORMAL 46 46% 
MODERATELY ABNORMAL 14 14% 
SEVERELY ABNORMAL 1 1% 
 
Chart 24: Left atrial size 
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Table 25: Right atrial size 
 
RIGHT ATRIAL SIZE NO OF PATIENTS PERCENTAGE 
NORMAL 74 74% 
ABNORMAL 26 26% 
 
Chart 25: Right atrial size 
 
 
 
Right atrial size was increased in 26 percent of patients in our study group. 
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Table 26: Left atrial clot 
 
LA CLOT NO OF PATIENTS PERCENTAGE 
PRESENT 2 2% 
ABSENT 98 98% 
 
Chart 26: Left atrial clot 
 
 
 
 
Left atrial clot was seen in only 2 patients in our study group. 
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DISCUSSION 
In our study 100 patients who satisfied the inclusion and exclusion 
criteria with Atrial Fibrillation were included, the mean age of our study 
population was 47.64 years. In our study we divided the patients into 4 Age 
groups, as follows < 20 years, 2. 21-40 years, 41-60 years – 30,> 60 years. In 
our study maximum number of patients were in the 41 -60 years age group 
followed by 21- 40 years age group while it was much less in other age group. 
This distribution is in contrast with previous studies done where the 
prevalence of AF shows a strong age dependence varying from 0.5% in patients 
aged <40 years to 5% in patients aged >65 years and nearly 10% amongst 
octogenarians [3–6]. Both the Framingham Heart Study and the Rotterdam 
Study estimated that the lifetime risk for development of AF in adults >40 years 
and at the age of 55 years respectively to be approximately 1 in 4.Novel risk 
factors for AF in young age are increasingly being discovered such as genetic 
causes, lifestyle factors (such as alcohol consumption, personality traits, and 
smoking), body mass index, and physical activity. In addition, it can also be 
argued that occult cardiac pathologies such as hypertension or ischemic heart 
disease may well be diagnosed in these patients if they are investigated 
thoroughly. A decreased mean age in our study may be due to above associated 
factors among patients in our study. 
In our study females were more in number than males. Out of 100 total 
patients 67 were females 33 were males. The male: female ratio was 2:1 in 
contrary to normal pattern. In general male patients are moreaffected than 
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female patients in AF but in our study female patients are more affected, since 
most common disease associated with our study population is rheumatic heart 
disease there may female preponderance ,this results was similar to study done 
by Dushyant S., et al52. 
Among our patients 63 percent had past history of RHD and on treatment 
for the same. In our Study Rheumatic heart disease was the most common 
etiologicalfactor associated with AF. These results are similar to previous 
studies done by Kannel WB., et al and Diker E., et al 48,50. One-fourth of 
patients with rheumatic valvular heart disease have Atrial Fibrillation (AF) [5]. 
Probability of development of AF is high in patients with MS, owing to Left 
Atrial (LA) dilatation in response to valve obstruction and the inflammatory and 
fibrotic changes caused by the rheumatic process [6,7]. With the onset of AF, 
there is an unexpected loss of the atrial involvement to ventricular filling and 
about 30% reduction in cardiac output 
The second most common predisposing factor in our study was systemic 
hypertension. Around 29 patients had history of treatment for SHT. This is 
similar with the study by Framingham76, who also found a significant 
association between SHT and AF. HTN is the most common cardiovascular 
disorder and AF is the most common clinically significant arrhythmia. Both 
conditions are associated with aging and often coexist.17–20 In some studies, 
up to 90% of AF patients are observed to be hypertensive (Figure 1).21–
23 Beyond the direct relations between AF and HTN, HTN is also associated 
with other cardiovascular co morbidities that increase risk for AF, including 
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coronary artery disease, heart failure, metabolic syndrome, chronic kidney 
disease, and sleep apnea.24–27Higher pulse pressure has also been shown to 
increase the risk of developing AF.28 In a prospective study involving 
Framingham Heart Study and Offspring participants, each 20 mm Hg increase 
in pulse pressure was associated with a 24% increased risk of AF over a 20-year 
follow-up. Notably, models were adjusted for mean blood pressure and other 
clinical risk factors for both AF and HTN. This suggests that increased pulse 
pressure may be an independent predictor of arterial stiffness and capture an 
additional modifiable AF risk element distinct from systolic hypertension.28 
During our evaluation 32 percent of patients had an elevated blood pressure 
while the rest of them had normal or low blood pressure. 
 Also about 17 patients with AF in our study had CAD as a possible 
etiological factor, and this conforms to the study by Kannel WB., et al and 
Crenshaw BS., et al48,49. The prevalence of CAD in patients with AF is from 
17% to 46.5% which is similar to our study while the prevalence of AF among 
patients with CAD is low and it is estimated from 0.2% to 5%. 
In our study group around 22 patients had history of treatment for 
diabetes mellitus and 13 patients had past history of COPD. COPD is not only 
an independent predictor for major adverse cardiac events but also a predictor of 
AF incidence [3, 4]. The rate of AF incident was inversely associated with 
forced expiratory volume in one second (FEV1). AF prevalence was higher in 
severe airflow obstruction subject than those with mild or moderate airflow 
obstruction [5, 6]. Moreover, the risk of AF hospitalization was higher among 
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the lower FEV1, especially for FEV1 < 60% [7]. Previous Studies have reported 
that the major cause of deaths in COPD patients is cardiovascular diseases 
(CVD) rather than respiratory failure and it is more likely to develop acute 
coronary syndrome and heart failure. Furthermore, COPD contributes most to 
the increased all-cause mortality of AF [8]. 
Among other diseases associated in patients with atrial fibrillation.In our 
study group thyroid disorders were seen in 5 patients( hyperthyroidism -2 & 
Thyrotoxicosis -3). AF occurs in up to 15% of patients with hyperthyroidism 
compared to 4% of people in the general population and is more common in 
men and in patients with triiodothyronine (T3) toxicosis. The incidence of AF 
increases with advancing age. Also, subclinical hyperthyroidism is a risk factor 
associated with a 3-fold increase in development of AF. Thyrotoxicosis exerts 
marked influences on electrical impulse generation (chronotropic effect) and 
conduction (dromotropic effect). Several potential mechanisms could be 
invoked for the effect of thyroid hormones on AF risk, including elevation of 
left atrial pressure secondary to increased left ventricular mass and impaired 
ventricular relaxation, ischemia resulting from increased resting heart rate, and 
increased atrial ectopic activity. Re-entry has been postulated as one of the main 
mechanisms leading to AF. AF is more likely if effective refractory periods are 
short and conduction is slow. Hyperthyroidism is associated with shortening of 
action potential duration which may also contribute to AF 
Different types of cardiomyopathy was seen in around 5 patients(HOCM-
3,DCM-1 & RCM 1), Increased left atrial size and volume along with impaired 
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left atrial function confer an increased likelihood of AF. Atrial septal defect was 
seen in a solitary patient. 
 Coming to presenting complaints an previous study done by Flaker, Greg 
C., et al study70 showed 78% of the patients with breathlessness and next 
commonest presentation was chest pain. Similarly another study done by 
Tischler et al 75 showed breathlessness in 62%of patients,’ palpitation’ in 33% 
patients, and giddiness in 12% patients, In our study predominant symptom was 
breathlessness similar to above studies with 78 patients presented with 
breathlessness followed by palpitation in 53% cases, rest of the common 
symptoms were chest pain (n=26) and pedal edema (n=35). Giddiness was seen 
only in six patients, weakness of limb in seven patients. 
Most of the patients actually had multiple symptoms.In our study 32 
patients presented with single complaints, while patients who had two 
complaints were also 32. Rest of 36 patients presented with two or more 
complaints. 
In our study personal habits like smoking and alcohol intake was seen in 
around 25% of cases. Smoking habit was seen in 16 patients and alcohol intake 
in 19 patients. Cigarette smoking and excessive drinking are important risk 
factors for incidence of AF 
Cardiac failure is seen in 37 percent of patients in our study group.We 
also evaluated the ejection fraction of all patients in our study group, In our 
study 71 % of the patients had normal ejection fraction and 29 patients had 
reduced EF Among that 16% of the patients had mildly abnormal,10% of the 
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patients had moderately abnormal, and the remaining 3% of them presented 
with severely abnormal EF, Presence of such  abnormal EF(LV systolic 
dysfunction) independently predicts the risk of stroke shown by  study on atrial 
fibrillation by researchers 69. The reported prevalence of AF in heart failure 
series ranges from 13% to 27%.12–16 In the Framingham Heart Study, 26% of 
patients developed both AF and heart failure.17 Moreover, the prevalence of AF 
in patients with heart failure increased in parallel with the severity of the 
disease, ranging from 5% in patients with mild to 10% to 26% among patients 
with moderate up to 50% in patients with severe heart failure.18 This results are 
in similar to our study. 
Next we evaluated the heart rate in our patient with 46% of patients had 
normal heart rate were as 5 patients had bradycardia and around 49% of patients 
had tachycardia. As we all know AF is conditions with irregularly irregular rate, 
it may be fast sometimes nu not necessarily. 
Further we evaluated the transthoracic echocardiographic finding in all patients 
of our study group 
To start with first let’s discuss the Left ventricular internal dimension during 
diastole which was abnormal i.e. Increased in 30 percent of patients in our study 
group. Among which 22 patients had mild increase in diameter and 8 patients 
had moderate increase in diameter. 4 Increased LV size as detected by 
echocardiography is a strong independent predictor of cardiovascular morbidity, 
especially in hypertensive men. In previous studies age and body weight and 
cardiovascular features such as the duration of atrial fibrillation, LV mass, 
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annular calcification, the severity of coronary artery disease, and hypertension 
have been related to left ventricular diameter 6-10. 
 Next we evaluated the regional wall motion abnormality which was seen 
in 15 patients in our study group. Regional wall motional abnormality has a 
direct influence on ejection fraction and left atrial size which in turn becomes a 
risk factor for developing AF. 
The left atrial size was abnormal in most of patients in our study group 
with around 61% patients having an abnormal sized left atrium. Among these 
61 patients there was mild increase in 46 patients, moderate increase in 14 
patients and severe increase in one patient. Occurrence of AF is known to 
correlate with LA size; the incidence of AF rises from 3% when the left atrial 
diameter is < 40mm to 54% if the left atrial diameter is > 40 mm. The left 
atrium (LA) has a reservoir and conduit function, and is an important regulator 
of left ventricular filling.[3] It also reflects an important electrophysiological 
substrate and has neurohumoral properties by releasing natriuretic peptides.[3,5] 
Those factors are closely related to left ventricular systolic and diastolic 
function.[3,6] LA enlargement itself is an important risk factor for incident 
AF[6–10], and is related to an increased stroke risk.[6–12] LA size is also a key 
determinant for the success of rhythm control strategies in patients with 
AF.[3,4] 
Similarly we evaluated the right atrial size which was increased only in 26 
patients in our study group. Atrial structural or electrical remodelling is 
commonly observed in patients with AF. However, this knowledge is mainly 
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based on LA studies, whereas little is known about the potential relationship 
between RA disease and pathophysiology of AF. Anatomical and histological 
changes in the RA in patients with AF have been recognized with recent 
advances in cardiac imaging tools and electrophysiology and a study done 
reported that about 1 in 5 AF events have a RA origin. Hence in our study too 
there is not much patients who had right atrial enlargement, which is 
comparatively of less incidence than left atrial enlargement. 
Left atrial clot was seen in only 2% of patients in our study group. This is 
similar to previous studies done where the incidence was around 1.5% among 
AF patients 
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SUMMARY 
 Atrial Fibrillation is the one of the most commonly encountered weak or 
irregular heart beat (arrhythmia) in our population. 
 This study was undertaken to study about clinical profile of Atrial 
fibrillation and its transthoracic echocardiography presentation.  
 A total of 100 patients who satisfied inclusion and exclusion criteria with 
atrial fibrillation were taken up for study, 
 After ethical committee clearance, and obtaining an informed consent, the 
patient’s History, clinical and laboratory data were collected and analysed 
statistically. 
 In our study females were more in number than males. Out of 100 total 
patients 63 were females, and 37 were males with a male: female ratio of 
1:1.7. 
 Most common age group was 41-60 years. 
 Rheumatic heart disease was the most common cause of AF in our study, 
 Systemic hypertension was the second most common cause for AF. 
 CAD was seen in 17 cases, Diabetes in 22 cases and COPD in 13 cases 
 Breathlessness was the most common complaint followed by palpitation. 
 Smoking habit seen in 16 patients and alcohol intake in 19 patients. 
 Cardiac failure seen in 37 percent of cases while ejection fraction was 
decreased in 29 patients. 
 Uncontrolled heart rate or tachycardia is seen in 49 percent of patients. 
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 Coming to ECHO findings increased LVIDd was seen in 30 patients 
 Regional wall motion abnormality seen in 15 percent of patients in our 
study group. 
 Increased left atrial size – the most common ECHO finding seen in atrial 
fibrillation was seen in 61 patients while increased right atrial size was 
seen in 26 patients. 
 We detected LA Clot only in a very few patients withAF because TTE 
has low sensitivity of detecting LA clot. 
 
 
CONCLUSION 
 
 To conclude from above study its clear rheumatic heart disease was found 
to be the most common cause of atrial fibrillation followed by dilated 
cardiomyopathy. Females were more affected as compared to males.Common 
presentations were shortness of breath, palpitations.Commonest finding in 
ECHO is increased left atrial size. A complete echocardiographic evaluation is 
must in patient diagnosed with atrial fibrillation, which helps in deciding the 
prognosis of the patient also helps in assessing the chances of developing 
thrombo-embolic episodes. Hence regular monitoring with ECHO is advisable 
in AF patients. 
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Proforma 
 
Clinico-etiological profile of Atrial Fibrillation and its correlation with Atrial size 
Name  
Age 
Sex 
Address 
 
Presenting complaints 
1.Palpitation 
2.Giddiness/ Syncope 
3.Chest pain 
4. Breathlessness 
5.Pedaledema 
6.Weakness of limbs 
7. others 
 
Past history: 
1.RHD 
2.CAD 
3.SHTN 
4.DM 
5.COPD 
6.Others 
 
Personal history: 
1.Alcoholic 
2.Smoker 
3.Substance abuse 
 
General examination: 
Consciousness: 
Pallor : 
Clubbing: 
Pedal edema: 
Elevated JVP: 
Signs of Hyperthyroidism: 
Vitals: 
Pulse Rate: 
Pulse Deficit: 
Blood Pressure 
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Systemic Examination: 
CVS: 
RS: 
P/A: 
CNS: 
 
Investigation: 
Hb: 
SERUM ELECTROLYTES: 
Lipid profile: 
TFT (optional): 
ECG: 
Chest X-ray: 
Echocardiogram (Transthoracic) 
LVIDd 
LVIDs 
EF: 
RWMA: 
MITRAL VALVE:                                   MS:                     MR 
AORTIC VALVE: 
LEFT ATRIAL SIZE 
RIGHT ATRIAL SIZE: 
LA CLOT/ VEGETATION: 
 
DIAGNOSIS: 
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MASTER CHART 
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KEY TO MASTER CHART 
    
 AGE: 
<20       - 1 
20-40   - 2 
40-60   - 3 
>60      - 4 
 
Presenting complaints 
1.Palpitation 
2.Giddiness/ Syncope 
3.Chest pain 
4. Breathlessness 
5.Pedal edema 
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KEY TO MASTER CHART: 
AGE: 
<20 - 1 
20-39 - 2 
40-59 - 3 
>60- 4  
 
Presenting complaints: 
1.Palpitation 
2.Giddiness/ syncope 
3.Chest Pain 
4.Breathlessness 
5.Pedal edema 
6.Weakness of limbs 
7. others  
 
Past history: 
YES- Y;    NO-N 
1.RHD 
2.CAD 
3.SHTN 
4.DM 
5.COPD 
6.Others 
 
Personal history: 
1.Alcoholic 
2.Smoker 
3.Substance abuse 
4.No 
 
Cardiac failure :  yes-Y ; no-N 
Heart rate: 
1.Slow: (<80/MIN) 
2.Controlled (80-110/MIN) 
3.Uncontrolled (rapid) ( 110/MIN )  
 
Blood pressure  
1.Hypertension (>140/90 mm of Hg) 
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2.normal  
 
Echo : 
LVIDd(Left ventricular internal Diameter in cm during diastole):- 
MEN        WOMEN 
Reference range: 4.2-5.9 → 1     3.9-5.3→1 
Mildly abnormal: 6.0-6.3 → 2     5.4-5.7→2 
Moderately abnormal: 6.4-6.8→3    5.8-6.1→3 
Severely abnormal: ≥ 6.9→4     ≥ 6.2→4 
 
Ejection fraction: 
Reference range: 
 ≥ 55→1  
45-54→2  
30-44→3  
< 30→4 
 
RWMA: 
Yes – Y 
No- N 
 
LA SIZE( Left Atrium Diameter in cm) 
MEN        WOMEN 
Reference range: 3.0-4.0→ 1     2.7-3.8→1 
Mildly abnormal: 4.1-4.6→ 2     3.9-4.2→2 
Moderately abnormal: 4.7-5.2→3    4.3-4.6→3 
Severely abnormal : ≥ 5.3→ 4     ≥4.7 →4 
 
RA SIZE( Right Atrium Major Dimension in cm):- 
Normal < 5.3 → 1 
Abnomal > 5.3 → 2 
 
LA Clot :- 
YES-  Y 
NO- N 
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CONSENT 
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ANTI-PLAGIARISM  
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ANTI-PLAGIARISM CERTIFICATE 
 
 
 
